08.21.25 -- The FDA Was Darned Near Perfect, Right?

Discover how Nanoform's patented Bio platform is revolutionizing biologics and peptide delivery. In this webinar, explore two breakthrough case studies—subcutaneous Trastuzumab with improved stability and syringeability, and inhalable Semaglutide for deep lung delivery. Learn how these innovations can boost patient comfort, compliance, and outcomes. Don’t miss insights shaping the future of patient-friendly therapies. Click here to learn more.

The heterogeneity of a biologic product has implications for the final therapy's safety and efficacy. Explore challenges associated with charged variants, including mAbs and fusion proteins.

Polymorph screening has evolved tremendously. The combination of high-throughput experimentation with fast and efficient characterizations and computational predictions is offering new screenings.

Accelerate your biologic development by adopting faster, more reliable clone selection methods that reduce time and resources while improving the likelihood of identifying stable, high-producing cell lines.

In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.

Gain insights into how expert teams and the right tools help build resilience into manufacturing systems and tackle small, often-overlooked issues before they become costly problems.

Review the evolution of injection devices and prefilled syringes, the benefits of training devices combined with patient education, and an empirical look at patient training.

Reconstructed nasal epithelium and CT-based 3D nasal casts provide more predictive, physiologically relevant models for assessing nasal drug delivery, improving accuracy in formulation development.

For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.

Discover a cost-effective, efficient technology solution that streamlines process development, reduces complexity, and enables a smooth transition from research to manufacturing.

Explore the challenges when moving a bioconjugate candidate from early development to clinic, along with integrated solutions for navigating this growing area of the biopharmaceutical industry.

Gain insight into the benefits of a next-generation CLD platform that delivers consistent quality, scalable performance and flexible expression solutions tailored to the demands of complex molecules.

Join Outsourced Pharma Online on September 3rd at 2pm ET for a virtual panel discussion on overcoming difficulties outsourcing development and manufacturing, how does a biopharma organization (of any size) handle a multi-CDMO coordination. Registration is free for this digital event.

Review our full range of support services to streamline manufacturing processes through to the commercialization of aseptic and lyophilized products.

This drug product filtration system operates using configurable recipe-controlled phases to automatically perform terminal sterilization prior to filling with maximum product recovery using standard flow kits.

We now serve more than half of the world’s leading biopharmaceutical companies, sharing their mission to expedite patient access to life-saving biologics.

Our end-to-end injectable services, comprehensive approach, and dedication to excellence provide convenient, easy-to-use, patient-centric therapies.

With a suite of analytical services and capabilities, we equip our clients with the insights and tools needed for successful biologics characterization and phase-appropriate process development.

Curia offers comprehensive development and manufacturing services to meet needs through the entire lifecycle of your sterile drug product. Leverage our in-depth expertise and capabilities at any scale.